Compound Files

Semaglutide (Hero SM): How the Once-Weekly GLP-1 Analog Works

The GLP-1 analog that started the modern era. How semaglutide was engineered, how it works, and what its landmark trials found.

Hero Peptides Research TeamUpdated Nov 20265 min read

Key facts
Class	GLP-1 receptor agonist
Developer	Novo Nordisk
Similarity to human GLP-1	About 94% sequence homology
Key modifications	Aib at position 8, Arg at 34, C18 fatty diacid on Lys26
Half-life (human studies)	About 7 days
Status	FDA approved (Ozempic 2017, Rybelsus 2019, Wegovy 2021)
Hero product	Hero SM

Native GLP-1 is a brilliant hormone with a terrible lifespan: it’s broken down in about two minutes. Semaglutide is what happens when chemists fix that problem. With three precise changes to the GLP-1 sequence, Novo Nordisk built a molecule that lasts about a week, and in doing so created the compound most of today’s metabolic research is measured against.

This guide covers semaglutide’s structure, how GLP-1 receptor agonism works, and the landmark trials that defined the class.

Best seller!

Retatrutide10 mg / 20 mg / 30 mgIn stock · ships Wed

from$94as low as $6.63/mg+ Add

Origin story: fixing GLP-1’s two-minute problem

GLP-1 is released by L cells in the gut after a meal. It increases insulin release when glucose is high, lowers glucagon, slows stomach emptying and signals fullness to the brain. But the enzyme DPP-4 cuts it apart within minutes, and the kidneys clear what’s left. Early GLP-1 compounds like exenatide and liraglutide stretched that window to hours or a day. Semaglutide was designed to reach a full week (Lau et al., 2015).

How semaglutide is built

Semaglutide keeps about 94% of the human GLP-1 sequence. Three changes do the heavy lifting:

Aib at position 8: Swapping alanine for aminoisobutyric acid blocks DPP-4, the enzyme that inactivates native GLP-1.
Arginine at position 34: Replacing lysine leaves only one lysine (position 26) available for the side chain, so the fatty acid attaches in exactly one place.
C18 fatty diacid on lysine 26: Attached through a hydrophilic linker, it binds strongly to albumin. Bound to albumin, semaglutide is shielded from breakdown and too large to be filtered by the kidneys quickly.

The result is a half-life of about seven days in humans. Tirzepatide and retatrutide later used the same albumin-binding strategy with a longer C20 chain. See our tirzepatide and retatrutide guides.

How GLP-1 receptor agonism works

The GLP-1 receptor is a class B G-protein-coupled receptor. When semaglutide binds, it activates the Gs protein and raises cAMP inside the cell. What happens next depends on the tissue (Drucker, 2018):

Tissue	Effect of GLP-1 receptor activation
Pancreatic beta cells	More insulin released, but only when glucose is elevated
Pancreatic alpha cells	Less glucagon released after meals
Stomach	Slower gastric emptying
Brain (hypothalamus, brainstem)	Increased fullness, reduced food intake
Heart and blood vessels	Studied for cardiovascular effects; receptors present in several cell types

The “glucose-dependent” part is key: GLP-1’s insulin effect fades as glucose normalizes, which is why GLP-1 agonists alone carry a low risk of low blood sugar. Our GLP-1 vs GIP vs glucagon explainer goes deeper.

The landmark trials

Trial	Population	Key finding
SUSTAIN-6 (2016)	3,297 adults with type 2 diabetes at high cardiovascular risk	Major cardiovascular events reduced vs placebo (hazard ratio 0.74)
STEP 1 (2021)	1,961 adults with obesity or overweight, no diabetes	Mean weight change −14.9% vs −2.4% on placebo at 68 weeks
SELECT (2023)	17,604 adults with cardiovascular disease and overweight, no diabetes	20% reduction in major cardiovascular events (hazard ratio 0.80)
FLOW (2024)	Adults with type 2 diabetes and chronic kidney disease	24% lower risk of major kidney outcomes

Sources: Marso et al., 2016; Wilding et al., 2021; Lincoff et al., 2023; Perkovic et al., 2024.

SELECT was a turning point. It showed cardiovascular benefit in people without diabetes, which pushed GLP-1 research well beyond glucose and weight.

Injectable vs oral semaglutide

Peptides are normally destroyed in the stomach. Oral semaglutide (Rybelsus) gets around this with an absorption enhancer called SNAC, which briefly raises local pH and helps a small fraction of the dose cross the stomach lining. Oral bioavailability is still low, which is why oral doses are much larger than injected ones. For lab work, Hero SM is supplied as a lyophilized powder for reconstitution.

Weak spots: what the safety data show

Gastrointestinal effects such as nausea, vomiting, diarrhea and constipation are the most common, mainly during dose escalation.
Class warnings include pancreatitis, gallbladder disease and thyroid C-cell tumors seen in rodent studies.
Lean mass: Body composition sub-studies show some of the weight reduction comes from lean tissue, an active area of research.

Semaglutide vs the next generation

Semaglutide is a single-receptor compound. Tirzepatide added GIP receptor activity and outperformed it head-to-head in SURMOUNT-5. Retatrutide adds glucagon on top. Researchers are also pairing semaglutide with the amylin analog cagrilintide (Hero CG), a combination known as CagriSema.

Handling semaglutide in the lab

Reconstitute Hero SM with bacteriostatic water following our reconstitution guide, and use the peptide calculator for concentration and syringe units. Store reconstituted vials refrigerated and avoid repeated freeze-thaw cycles.

Semaglutide FAQ

How long does semaglutide last?

Its half-life in human studies is about seven days, thanks to albumin binding through its C18 fatty diacid side chain.

Is semaglutide the same as Ozempic and Wegovy?

Ozempic, Wegovy and Rybelsus are brand names for approved semaglutide products. Semaglutide is the compound itself.

What is Hero SM?

Hero SM is Hero Peptides’ research-grade semaglutide, supplied as a lyophilized powder for laboratory research use only.